Status:

TERMINATED

Melanoma Accuracy Study; Phase 2

Lead Sponsor:

Nova Scotia Health Authority

Conditions:

Melanoma

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to evaluate the process, accuracy and patient outcomes of pre-screening dermatology referrals in a clinical setting by a qualified nurse. The long-range goal of the propos...

Detailed Description

The purpose of this study is to evaluate the process, accuracy and patient outcomes of pre-screening dermatology referrals in a clinical setting by a qualified nurse using a dermatoscope, triaging sus...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • New referral from a general practitioner to a dermatologist
  • Males and females, over the age of 18 are eligible to participate
  • Written informed consent from the patient
  • Lesion or mole is new, changing color, growing rapidly or has a change in sensation
  • Willing to have the lesion excised if necessary per standard of care
  • Ability to complete the imaging procedure and willing to complete a basic history
  • Pigmented lesion considered low, moderate or high risk for melanoma by a general practitioner
  • Exclusion Criteria
  • Lesions which are not amenable
  • Participant unable to read, understand or sign consent
  • Participant under active care by a dermatologist
  • Lesion \<2 mm or \>15mm in diameter
  • Lesion located on areas of scars, crusts, psoriasis, eczema or similar skin conditions
  • Lesion on hair covered areas (e.g. scalp, beard, mustache) where hair cannot be removed
  • Lesions located on genitalia not accessible to equipment
  • Lesions located in an area that has previously biopsied or subjected to any kind of surgical or ablative procedure
  • Lesion with foreign matter, e.g. tattoo or splinter
  • Lesion and/or reference located on acute sunburn
  • Skin surface not measurable, e.g. lesion on a stalk
  • Skin surface not accessible, e.g. inside ears, ears, under nails
  • Skin not intact (measurement area), e.g. bleeding or with clinically noticeable ulceration
  • Lesions located within 1cm of the eye
  • Lesions light in pigment or thick and nodular
  • Participants not willing to have the lesion excised

Exclusion

    Key Trial Info

    Start Date :

    February 28 2018

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    October 10 2018

    Estimated Enrollment :

    121 Patients enrolled

    Trial Details

    Trial ID

    NCT03464604

    Start Date

    February 28 2018

    End Date

    October 10 2018

    Last Update

    November 23 2022

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Nova Scotia Health

    Halifax, Nova Scotia, Canada, B3A 4A7

    2

    Nova Scotia Health

    Halifax, Nova Scotia, Canada, B3H 4A7